Compass pathways stock forecast.

See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...

17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.

Kabir Nath, COMPASS Pathways Chief Executive Officer said, ... sold its remainder position on Friday for $121.6 million, according to disclosure by the local Indian stock exchange.Oct 18, 2023 · Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.Web2 de set. de 2022 ... ... stock could be Wall Street's biggest winner of the 2020s. Listen to the Podcast ➡️Spotify: https://open.spotify.com/show ...View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...Web

Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.

See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Web

Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis. How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....

Dec 1, 2023 · COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.Analyst Price Forecast Suggests 309.83% Upside. As of April 6, 2023, the average one-year price target for COMPASS Pathways Plc American Depository Shares is $42.38. The forecasts range from a low ...Web

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...Web1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...

Dec 1, 2023 · See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, ... CMPS Stock Price Forecast. Long-term, we love COMPASS Pathways.WebWe are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases; Events; Presentations; SEC filings & annual reports; Our annual review; Stock information. Stock quote & chart; Historical price lookup; Analyst Coverage; Split history; Corporate ...markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebUK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …

COMPASS Pathways plc (CMPS) latest earnings report: revenue, EPS, surprise, history, news and analysis.

Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...

May 6, 2023 · On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) has given the green light for three new current procedural terminology (CPT) codes for psychedelic ... May 6, 2023 · On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) has given the green light for three new current procedural terminology (CPT) codes for psychedelic ... Upgrade Your Account ... COMPASS Pathways plc NASDAQ: CMPS is a United Kingdom-based mental healthcare company developing psilocybin therapy through late-stage ...16 de ago. de 2023 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...2 de nov. de 2023 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...May 26, 2023 · COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center. LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health ...Nov 29, 2022 · That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...

Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The average price target for CMPS is …WebShares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes in the live stock price.Instagram:https://instagram. mfs international equitytangem wallet reviewhilary palm springsindian pcb COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center. xlk stock holdingsinteractive brokers pro cost Next reporting date. March 27, 2024. EPS forecast (this quarter) -$0.22. Annual revenue (last year) $233.0K. Annual profit (last year) -$152.4M. natrual gas stocks Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Some... Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst...Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ...COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...